SEHK:1877Biotechs
Has Junshi’s 200% Rally Priced in the Latest Immunotherapy Breakthrough?
If you’re watching Shanghai Junshi Biosciences stock and wondering what to do next, you’re not alone. After all, this biotech name has delivered a jaw-dropping 201.3% return year-to-date. Over the past year, it’s held onto those gains with a 216.5% surge, even if the rollercoaster over five years shows a different side with a decline of 35.2%. So is this momentum here to stay, or are risks building beneath the surface?
Much of the optimism swirling around Shanghai Junshi Biosciences traces...